Target audience

Pulmonologists
Trainees in pulmonology
Research fellows involved in research on airway inflammation/oxidative stress
Laboratory technicians performing lung function tests, methacholine challenge or exhaled breath tests

Educational aims

Discuss the global training needs
Apply key epidemiological concepts to the clinical practice
Discuss the principles behind control and elimination strategies
Evaluate the TB elimination programme in own Country
Use new tool to diagnose tuberculosis (TB) infection and disease
Treat latent TB infected individuals and drug-susceptible TB cases (adults and children) according to the last scientific evidence
Apply the principles underlying treatment of multi-drug resistant (MDR-) and extensively drug-resistant (XDR-) TB cases
Manage adverse events of MDR- and XDR-TB treatment
Design clinical trials for new drugs aimed at treating TB infection and disease
Identify the priority areas for research to reach TB elimination
Discuss the career opportunities in respiratory medicine in the TB elimination phase

Introduction, learning objectives and revision of training material G.B. Migliori (Tradate, Italy)
Results of the FP7 TB PAN-NET EU funded project V. Katalinic (Zaghreb, Crotia)
Filling the global training gap L. D' Ambrosio (Tradate, Italy)
TB elimination: theory and practice in Europe G.B. Migliori (Tradate, Italy)
Defining or redefining TB Elimination. ‘Fast’ Food for Thought D. Manissero (Geneva, Switzerland)
The US experience L. Reichman (New Jersey, USA)
Perspectives on the new drugs pipeline L. Reichman (New Jersey, USA)
News on treatment of LTBI I. Abubakar (London, UK)
General principles G. Sotgiu (Sassari, Italy)
Trials for TB infection and disease drugs: special aspects I. Abubakar (London, UK)
Trials for TB infection and disease drugs: special aspects J-P. Zellweger (Fribourg, Switzerland)
Trials for TB infection diagnostics: designing a protocol D. Cirillo (Milan, Italy)
Trials for TB disease diagnostics: designing a protocol V. Katalinic (Zaghreb, Crotia)
New guidelines to manage MDR-TB M. Dara (Geneva, Switzerland)
A Phase III Study of a New Inhaled Therapy for MDR TB - Ficticionid Participants presentation
LTBI Protocol Participants presentation
Research priorities for TB elimination low prevalence countries Participants presentation
Country A Participants presentation
Country B Participants presentation
Country B Presentation Participants presentation